1281816-04-3

Basic information

• Product Name: N²'-deacetyl-N²'-[3-[[1-[[4-[[[(1S)-5-amino-1-carboxypentyl]amino]carbonyl]cyclohexyl]methyl]-2,5-dioxo-3-pyrrolidinyl]thio]-1-oxopropyl]maytansine
• CAS NO: 1281816-04-3
• Molecular Weight: 1103.73
• Mol File: 1281816-04-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: N²'-deacetyl-N²'-[3-[[1-[[4-[[[(1S)-5-amino-1-carboxypentyl]amino]carbonyl]cyclohexyl]methyl]-2,5-dioxo-3-pyrrolidinyl]thio]-1-oxopropyl]maytansine(CAS DataBase Reference)
• NIST Chemistry Reference: N²'-deacetyl-N²'-[3-[[1-[[4-[[[(1S)-5-amino-1-carboxypentyl]amino]carbonyl]cyclohexyl]methyl]-2,5-dioxo-3-pyrrolidinyl]thio]-1-oxopropyl]maytansine(1281816-04-3)
• EPA Substance Registry System: N²'-deacetyl-N²'-[3-[[1-[[4-[[[(1S)-5-amino-1-carboxypentyl]amino]carbonyl]cyclohexyl]methyl]-2,5-dioxo-3-pyrrolidinyl]thio]-1-oxopropyl]maytansine(1281816-04-3)

Safety Data

• Hazardous Substances Data: 1281816-04-3(Hazardous Substances Data)

Usage

Uses

Lys-SMCC-DM1 is designed to eradicate cancer cells that express the target antigen on their cell surface.

Upstream product

• 139504-50-0 N^2'-deacetyl-N^2'-(3-mercapto-1-oxopropyl)maytansine 
• 56-87-1 L-lysine 
• 57103-68-1 maytansinol 
• 1228105-51-8 SMCC-MDC 
• 64987-85-5 4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid N-succinimidyl ester 
• 77668-69-0 (1⁴S,1⁶S,3²R,3³R,2R,4S,10E,12E,14R)-8⁶-chloro-1⁴-hydroxy-8⁵,14-dimethoxy-3³,2,7,10-tetramethyl-1²,6-dioxo-7-aza-1(6,4)-oxazinana-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-4-yl methyl-L-alaninate 
• 1452404-52-2 Fmoc-N-Me-L-Ala-maytansinol 

Relevant articles and documents

Metabolites of antibody-maytansinoid conjugates: Characteristics and in vitro potencies

Several antibody-maytansinoid conjugates (AMCs) are in clinical trials for the treatment of various cancers. Each of these conjugates can be metabolized by tumor cells to give cytotoxic maytansinoid metabolites that can kill targeted cells. In preclinical

COMPOUNDS AND METHODS FOR THE TREATMENT OF ERB B2/NEU POSITIVE DISEASES

Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided.